Knight Therapeutics (TSE:GUD)
TSX:GUD
Want to see TSE:GUD full AI Analyst Report?
GUD Stock Chart & Stats
C$7.65
-C$0.03(-0.46%)
At close: 4:00 PM EST
C$7.65
-C$0.03(-0.46%)
Day’s Range― - ―
52-Week RangeC$5.50 - C$7.74
Previous CloseN/A
Volume40.10K
Average Volume (3M)48.52K
Market Cap
C$739.18M
Enterprise ValueC$725.11M
Total Cash (Recent Filing)C$95.28M
Total Debt (Recent Filing)C$77.91M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
May 07, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding98,034,744
10 Day Avg. Volume49,308
30 Day Avg. Volume48,518
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)0.79
Price to Sales (P/S)1.34
P/FCF Ratio8.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$8.98Price Target Upside17.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)C$484.73M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a large equity base give Knight flexibility to absorb earnings swings, fund licensing or acquisitions, and sustain operations without urgent refinancing. This conservative capital structure supports durability through revenue cycles and strategic investments.
Improved Cash GenerationOperating cash flow strengthened into 2025 and free cash flow was very strong, providing internal funding for marketing, licensing milestones, and working capital. Improved cash-generation reduces reliance on external capital and supports durable commercialization and deal execution.
Recurring Revenue Growth & Commercial ModelSteady revenue growth (strong multi-year trend and +8.8% in 2025) reflects demand for its in‑licensed portfolio. Knight's commercialization capabilities and footprint across Canada and Latin America provide recurring sales channels that support sustained top-line expansion.
Bears Say
Inconsistent ProfitabilityNet income has flipped between profits and losses across years and returned to a loss in 2025, demonstrating inconsistent profitability. This undermines long‑term margins, limits retained earnings to fund growth, and weakens predictability of cash available for reinvestment.
Cash Flow VolatilityHistorical swings in operating and free cash flow — including negative OCF in 2020 and deep negative FCF in 2021 — indicate cash generation is timing-sensitive. Such volatility can pressure liquidity, force opportunistic financing, and constrain deal-making when cash tightens.
Dependence On Licensing And RegulationReliance on in‑licensing and external regulatory and reimbursement processes exposes revenue to third‑party timelines and decisions. Delays or unfavorable pricing can defer launches, compress margins, or limit market access, creating structural execution and revenue risk over time.
Knight Therapeutics News
GUD FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was C$5.50 and its highest was C$7.74 in the past 12 months.
What is Knight Therapeutics’s market cap?
Knight Therapeutics’s market cap is C$739.18M.
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 8 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on Mar 19, 2026. The company reported C$0.09 earnings per share for the quarter, beating the consensus estimate of -C$0.004 by C$0.094.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is 0.03.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 98,034,744 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of C$0.09 in its last earnings report, beating expectations of -C$0.004. Following the earnings report the stock price went up 2.107%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in TSE:GUD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Knight Therapeutics
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
GUD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Knight Therapeutics reported strong financial performance with record revenues and EBITDA, significant growth driven by key products, and an improved financial outlook for 2025. The expansion of the oncology portfolio and increased credit facility provide a solid foundation for future growth. However, challenges were noted with regulatory setbacks in Brazil and Canada and a financial asset loss, though these do not overshadow the overall positive trends and achievements.View all TSE:GUD earnings summariesGUD Stock 12 Month Forecast
Average Price Target
C$8.98
▲(17.43% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
Organigram Global
―
Aurora Cannabis
―
Cronos Group
―
HLS Therapeutics Inc
―
Options Prices
Currently, No data available
---